Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annu...(intended utilization of ourproduct candi...),Health

Date:12/3/2008

intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "may," "potential," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, and the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE Micromet, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Micromet, Inc. Reports Second Quarter 2008 Financial Results
2. Micromet, Inc. Reports First Quarter 2008 Financial Results
3. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
4. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
5. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
6. Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast
7. Thoratec Presentation at Piper Jaffary Conference to be Webcast
8. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
9. Medco to Webcast 2008 Analyst Day Conference
10. Leading Physicians To Host Medical Device Related Infection Prevention CME Webcast
11. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results